

**ECOFINITY ATOMIX LIMITED  
(FORMERLY KNOWN AS ARYAVAN ENTERPRISE LIMITED)**

**CIN: L52100GJ1993PLC018943**

**ADDRESS: 308, SHITAL VARSHA ARCADE, OPP. GIRISH COLD DRINKS, C. G. ROAD, NAVRANGPURA,  
AHMEDABAD, GUJARAT – 380 009**

**E-MAIL: INVESTOR.DEEPTI@GMAIL.COM | MOBILE NO: +91 9824136618**

---

**03<sup>rd</sup> December, 2024**

**To,  
BSE Limited**

Phiroze Jeejeebhoy  
Towers, Dalal Street,  
Mumbai 400-001  
Maharashtra, India

**Scrip Code: 539455**

Dear Sir/Madam,

**Subject: Acquisition of the Partnership**

This is to inform you that, the Company has acquired 60% of the stake in the M/s. Padmavati Chemicals, a partnership firm by execution of the Partnership Deed executed on 03<sup>rd</sup> December, 2024.

We enclose herewith the details required under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No.SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated July 13, 2023 as an Annexure-1 to this letter.

**FOR, ECOFINITY ATOMIX LIMITED  
(Formerly known as Aryavan Enterprise Limited)**

**PRAFULLBHAI PATEL  
MANAGING DIRECTOR  
DIN: 08376125**

**ANNEXURE: 1**

**Details as per Regulation 30 of SEBI (LODR) Regulations, 2015**

<b>Sr. No.</b>	<b>Particulars</b>	<b>Details</b>
1	Name of the target entity, details in brief such as size, turnover etc.	M/s. Padmavati Chemicals.  Turnover as on 31 <sup>st</sup> March, 2024 is Rs. 12.70 Crores
2	Whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same. is done at "arm's length".	Yes.  The Company has passed the special resolution in 32 <sup>nd</sup> Annual General Meeting held on Saturday, 28 <sup>th</sup> September, 2024 u/s 188 for approval of Related Party Transaction.  The transaction is carried out at Arm's length.
3	Industry to which the entity being acquired belongs	Drugs Intermediaries and chemicals etc.
4	Objects and impact of acquisition (including but not limited to), disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity.	The Object of the acquisition is to expand the business presence with the existing business entity having wide experience of manufacturing in pharma industry.
5	Brief details of any governmental or regulatory approvals required for the acquisition.	N.A.
6	Indicative time period for completion of the acquisition.	Partnership Deed Executed on 3 <sup>rd</sup> December, 2024
7	Consideration whether cash consideration or share swap or any other form and details of the same.	Cash Consideration as a Partner's Capital in Partnership Firm to acquire 60% of shares in the above-referred firm.
8	Cost of acquisition and/or the price at which the shares are acquired.	Cash Consideration as a Partner's Capital in Partnership Firm to acquire 60% of shares in the above-referred firm.
9	Percentage of shareholding/control acquired and/or number of shares acquired	Cash Consideration as a Partner's Capital in Partnership Firm to acquire 60% of shares in the above-referred firm.
10	Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief)	M/S. PADMAVATI CHEMICALS is partnership firm having its factory premises at PLOT NO. 5101, PHASE-III, GIDC INDUSTRIAL ESTATE, VAPI-396195. The firm was formed vide partnership deed 26 <sup>th</sup> March, 1998 which was further amended on 1 <sup>st</sup> April, 2007.  The firm consists of two partners i.e. Mr. Prafullchandra Vitthalbhai Patel and Mr. Jasantbhai Shankarlal Patel. The firm has been carrying on business of manufacturing and sale of Pharma intermediates, other allied chemicals since its incorporation. The partners have vast experience in the line of business and there has been continuous growth in the business of the firm over the years.